Skip to main content

SELLAS Life Sciences Group, Inc 10-Q for FY2026 Q3

SELLAS Life Sciences Group, Inc. (SLS)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 12, 2026

About this 10-Q

SELLAS Life Sciences Group, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

SELLAS Life Sciences Group said the REGAL study reached 80 deaths, triggering final analysis; preliminary overall survival results are expected in November 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$10.09M
compared with a net loss of $6.79M a year earlier
Diluted EPS
-$0.05
compared with -$0.06 a year earlier